risankizumab
Risankizumab targets this specific IL-23 subunit.
What is the p19 subunit?
Upadacitinib's selective inhibition of this JAK isoform distinguishes it from other JAK inhibitors.
What is JAK1?
This Novartis IL-17A inhibitor is a monoclonal antibody in PsA and was among the first IL-17 inhibitors approved.
What is Cosentyx (secukinumab)?
This head-to-head Phase 3 trial showed upadacitinib superiority over abatacept in biologic-inadequate responders in RA.
What is SELECT-CHOICE?
This infection, caused by varicella-zoster virus reactivation, occurs at increased rates with JAK inhibitors versus some biologics.
What is herpes zoster (shingles)?
This AbbVie trial studied patients with PsA who were csDMARD-IR?
What is the Keepsake1 trial?
This is the approximate half-life of upadacitinib, which supports once-daily dosing.
What is 8–14 hours?
This J&J IL-23 inhibitor is approved in PsA with a dosing interval of 100mg Q8W, but consistently includes data for Q4W dosing.
What is Tremfya (guselkumab)?
This is the key distinction between prevalence and incidence.
What is that prevalence reflects how many patients have the condition at a given time, whereas incidence reflects new cases occurring over a defined period?
This is a new metabolic adverse event that can occur with upadacitinib and should be part of diabetic patient monitoring.
What is hypoglycemia?
This is the approximate elimination half-life of risankizumab in PsA.
What is approximately 28 days?
upadacitinib is metabolized primarily through this hepatic pathway, making liver function assessment important during therapy.
What is CYP3A4?
This Roche IL-6 receptor inhibitor is an alternative pathway agent that rapidly suppresses CRP levels.
What is Actemra (tocilizumab)?
This UCB dual IL-17A/F inhibitor differentiates itself by blocking both isoforms and was studied in the BE BOLD head-to-head trial versus risankizumab.
What is Bimzelx (bimekizumab)?
Only studied for 24 weeks, with an additional 12 week safety follow up period.
This boxed warning class includes serious infections, malignancy, major adverse cardiovascular events, and thrombosis.
What are class-wide JAK inhibitor boxed warnings?
This guideline classification includes: Psoriasis, Dactylitis, Enthesitis, Axial Disease, Nail Psoriasis, Peripheral Arthritis
What are the 6 PsA GRAPPA Domains?
A rheumatologist asks whether upadacitinib is primarily dependent on renal clearance and whether dose adjustment is required for renal impairment. What is the key response?
What is that upadacitinib is eliminated through multiple routes, and no dose adjustment is required for mild, moderate, or severe renal impairment; it has not been studied in end-stage renal disease?
This is a new IL-23 is an oral pill approved in March 2026 for moderate-to-severe plaque psoriasis.
What is Icotyde (icotrokinra)?
This Eli Lilly JAK1/2 inhibitor did not meet the noninferiority safety standard compared to a TNFi for the time to first VTE in high-risk RA patients
What is Olumiant (baricitinib)?
This post-marketing oral surveillance study in tofacitinib helped trigger broader regulatory scrutiny of the JAK inhibitor class.
What is ORAL Surveillance?
The Keepsake studies included assessment of this PsA manifestation using measures such as mNAPSI and fingernail physician global assessment.
What is nail psoriasis?
If a patient is on birth control, is there an increased risk of VTE when using Upa?
In a univariate analysis, oral contraceptive or hormonal replacement therapy use were not significantly associated with risk of VTE among patients receiving Upa.
This Bristol Myers Squibb T-cell costimulation modulator is a biologic that works by blocking the secondary signals that T-cells need for full activation.
What is Orencia (abatacept)?
Minimal Disease Activity (MDA) for PsA requires a patient to meet at least 5 out of these 7 specific clinical criteria.
What is Tender joint count, Swollen joint count, PASI OR BSA, Patient pain, Patient global disease activity, HAQ-DI, Enthesitis?
This is not recommended during treatment and for four weeks after the last dose of upadacitinib
What is breastfeeding?